Advancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
“There has been a real reticence to engage in development programs for neuroprotective interventions because of the long timeline necessary to bring a product to market,” said Dr. Goldberg, professor and chair, Byers Eye Institute, Stanford University, Palo Alto, CA.
“Many researchers . . . have identified treatments that could maintain the viability of retinal ganglion cells (RGCs) or even augment or enhance the function of residual RGCs, and the threshold has been lowered to bring these modalities into clinical testing,” he said.